Sign in
Active, not recruitingNo phase

Clinical Trial to Evaluate the Efficacy and Safety of MegaCarti® in Knee Cartilage Defects

Key facts

Who runs it
L&C Bio
Where
South Korea4 sites in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
90 people enrolled
Started
16 Apr 2020
Expected to end
31 Jan 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • MegaCarti®
  • Microfracture
Record updated
30 June 2022

Who can take part

Age
19 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (22)Hide the full registry criteria

Who can take part

  • 19 years to 65 years
  • Patients or legal representatives who voluntarily decide to participate in the clinical trial, after which sign the consent form
  • Defect: International Cartilage Repair Society(ICRS) Grade III or IV single defect chondral lesion on knee cartilage
  • Patients whose primary lesion site can be designated as one section of the knee joint, and the area can be determined as the main cause of clinical symptoms
  • knee cartilage defect size : Below 10 ㎠

Who cannot take part

  • Patients who underwent surgery related to cartilage defect treatment, such as microfracture, autologous chondrocyte therapy within the past 1 year (Possible for HTO surgery)
  • When screening, Patients who received intra-articular hyaluronic acid or steroid injections in the knee within 3 months
  • When screening, Patients who took oral steroid within 1 month
  • Patients who participated in other clinical trials within three months before screening
  • Patients who have autoimmune diseases (Ex. Rheumatoid arthritis)
  • Patients taking immunosuppressive drug, or having immune disorder
  • Patients with a history of cancer within the past five years
  • Patients who have chronic renal failure, active hepatitis, or poor blood sugar control
  • Drug and alcohol addiction / dependence or mental disorder
  • Patients with risk factor for bleeding (Patients taking antithrombotic drugs other than aspirin)
  • Patients who have systemic or localized knee infection
  • When screening, Patients who have clinically significant abnormalities in blood, serum, or urine tests
  • Patients who can't take MRI scan
  • BMI index : 30 ㎏/㎡ or over
  • Patients who have gout or gout history in the knee
  • When screening, Women who are pregnant or breast-feeding, or women who are planning for pregnancy during the clinical trial, or women who have a possibility of pregnancy but do not use medically accepted methods of contraception
  • Other than above, patients who are judged by medical investigator to be considered unsuitable for this clinical trial

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The MegaCarti® is the decellularized allogeneic cartilage and acts as a cover after bone marrow stimulation to prevent the loss of blood clots and induces cartilage regeneration by assisting in the location of stem cells derived from bone marrow.

Read full original descriptionShow less

The MegaCarti® is applied after Microfracture treatment on patients with Knee Cartilage Defects. The cartilage regeneration, which is a primary endpoint, is compared to the Microfracture group through MOCART evaluation. In addition, the improvement of pain and the recovery of Normal Range of motion are compared to the Microfracture group through secondary endpoints. Then, long-term follow-up study for 5 years is conducted to the experimental group.

The 2 groups in the trial

  • MegaCarti® application after microfractureTreatment being tested

    The experimental group is applied with MegaCarti® after microfracture. Afterwards, they visit at 6 weeks, 12 weeks, 24 weeks, and 48 weeks to conduct examinations and assess Questionnaires. Long-term follow-up Study is performed to subject that completes 48-week visit, at every 6 months for 5 years.

    Treatment: MegaCarti® and Microfracture

  • Microfracture onlyExisting treatment, for comparison

    The control group undergoes microfracture and they visit at 6 weeks, 12 weeks, 24 weeks, and 48 weeks after surgery to conduct examinations and assess Questionnaires.

    Treatment: Microfracture

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Clinical Trial to Evaluate the Efficacy and Safety of MegaCarti® ; Cartilage Defect Treatment Assisting Cartilage Regeneration in Knee Cartilage Defects : Multicenter, Independent Evaluator and Subject Blinded, Microfracture Comparative, Superiority, Randomized, Confirmatory Clinical Study and 5 Years Follow up Study
Record updated
30 June 2022